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The site on the HIV-1 gp120 glycoprotein that binds
the CD4 receptor is recognized by broadly reactive
antibodies, several of which neutralize over 90% of
HIV-1 strains. To understand how antibodies achieve
such neutralization, we isolated CD4-binding-site
(CD4bs) antibodies and analyzed 16 co-crystal struc-
tures –8 determined here– of CD4bs antibodies from
14 donors. The 16 antibodies segregated by recogni-
tion mode and developmental ontogeny into two
types: CDR H3-dominated and VH-gene-restricted.
Both could achieve greater than 80% neutraliza-
tion breadth, and both could develop in the same
donor. Although paratope chemistries differed, all
16 gp120-CD4bs antibody complexes showed1280 Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc.geometric similarity, with antibody-neutralization
breadth correlating with antibody-angle of approach
relative to the most effective antibody of each type.
The repertoire for effective recognition of the CD4
supersite thus comprises antibodies with distinct
paratopes arrayed about two optimal geometric ori-
entations, one achieved by CDR H3 ontogenies and
theother achievedbyVH-gene-restrictedontogenies.INTRODUCTION
Successful vaccines often recapitulate effective immune re-
sponses induced by natural infection. In the case of HIV-1, anti-
bodies capable of neutralizing about half of circulating strains
develop after years of chronic infection in about half of examined
donors (Hraber et al., 2014). Isolation and mapping of these
neutralizing responses show that they target most of the
exposed surface of the prefusion mature closed state of the
HIV-1 Env spike (Julien et al., 2013; Lyumkis et al., 2013; Pancera
et al., 2014). Despite this broad targeting, highly effective anti-
bodies develop preferentially against just a few sites of vulnera-
bility on HIV-1 Env. These ‘‘supersites’’ of vulnerability have been
the focus of intense vaccine interest. Each supersite appears
to be targeted by broadly neutralizing antibodies that arise in
many infected individuals, by broadly neutralizing antibodies
with diverse modes of recognition, and by broadly neutralizing
antibodies with diverse B cell ontogenies (reviewed in Kwong
and Mascola, 2012; West et al., 2014). Thus the human immune
system has multiple avenues by which to generate effective an-
tibodies against these supersites, thereby providing a rationale
for their suitability as focuses of vaccine efforts.
One of these supersites, the CD4 supersite, is the site of bind-
ing for the CD4 receptor on the HIV-1 gp120 envelope glycopro-
tein. All primate immunodeficiency viruses recognize CD4 as
the primary attachment molecule on the cell surface (Hoxie
et al., 1988; McClure et al., 1987), and therefore, despite the
great genomic and hence antigenic variation between HIV-1
strains, the CD4bs is relatively well conserved (Kwong et al.,
1998; Lyumkis et al., 2013; Pancera et al., 2014). Potent broadly
neutralizing CD4-binding-site (CD4bs) antibodies are frequently
observed during the chronic stage of infection (Binley et al.,
2008; Li et al., 2007; Lynch et al., 2012; Pancera et al., 2014;
Walker et al., 2010), and numerous CD4bs antibodies have
been identified (Burton et al., 1994; Corti et al., 2010; Georgiev
et al., 2013; Liao et al., 2013; Scheid et al., 2011; Wu et al.,
2010; Wu et al., 2011; Zhu et al., 2013). Analysis of co-crystal
structures of core gp120s with three of these CD4bs antibodies,
b12, VRC01, and CH103, reveals distinct modes of structural
interaction (Liao et al., 2013; Zhou et al., 2007, 2010), all of
which involve substantial interactions with the conformationally
invariant gp120 outer domain.
Additional antibody co-crystal structures (Zhou et al., 2013),
however, showed that CD4bs antibodies from different donors
could have similar modes of recognition and similar B cell
ontogenies, suggesting that the repertoire of effective CD4bs
antibodies might be limited. Because an understanding of the
variation in binding characteristics of antibodies specific for a
supersite is expected to provide insight regarding how such an-
tibodies might be induced in the general population, we sought
to study antibody recognition of the CD4 supersite in multiple
donors. We used antigen-specific probes to isolate CD4bs
antibodies from diverse germline VH genes. We determined co-
crystal structures with the HIV-1-Env gp120 glycoprotein for
these and for previously identified antibodies HJ16, 1B2530,
8ANC131, and 8ANC134 (Corti et al., 2010; Scheid et al., 2011)
and characterized B cell ontogenies and paratope chemistries.
The repeated observation of similar CD4bs antibodies in 14
donors provided a means to delineate the repertoire for effec-
tive recognition of the CD4 supersite. The results define struc-
tural geometries, recognized surfaces, paratope chemistries,
and developmental pathways of CD4bs recognition, thereby
providing a population-level understanding of antibodies target-
ing the CD4 supersite as well as a catalog from which to choose
optimal templates for vaccine re-elicitation.RESULTS
Identification of CD4bs Antibodies with Diverse
Germline Origin Genes
To provide a more comprehensive view for how human anti-
bodies recognize the CD4 supersite, we sought to identify
CD4bs antibodies from additional donors. In particular, we
were interested in determining whether highly effective neutral-
izing antibodies could originate from heavy-chain germline
genes other than VH1-2 or VH1-46, the germline origin genes
from which virtually all previously identified effective CD4bs an-
tibodies derive. Sera from donors 44, C38, and Z258 showed a
substantial reduction in neutralization when adsorbed with the
RSC3 probe, a modified core gp120 designed to retain only
the outer domain contact of CD4 (Wu et al., 2010). With donor
44, we used RSC3 sorting (Wu et al., 2010) and PCR recovery
of individual B cell antibody variable regions (Scheid et al.,
2009; Tiller et al., 2008) to isolate an antibody named ‘‘44-
VRC13.01’’ (named for ‘‘donor-antibody lineage.clone’’; after
the first mention of the complete antibody name, we refer to
each antibody by its lineage name) (Figure S1). VRC13 utilized
a VH gene derived from VH1-69 (Figure S1) and neutralized
82% of circulating HIV-1 isolates (Table S1). From donor C38,
we isolated two antibodies: C38-VRC16.01 and C38-VRC18.02
(Figure S1). VRC16 utilized a VH gene derived from VH3-23 and
neutralized 58% of HIV-1 strains; VRC18 utilized a VH gene
derived from VH1-2, was highly similar to an NGS-derived anti-
body from donor C38 (Zhu et al., 2013), and neutralized 67%
of HIV-1 strains (Table S1). From donor Z258, we isolated anti-
body Z258-VRC27.01. This antibody utilized a VH gene derived
from VH1-2 and neutralized 78% of HIV-1 strains (Figure S1
and Table S1). Altogether, we identified four potent and broadly
neutralizing CD4bs antibodies, two of which were derived from
VH genes not previously observed in effective CD4bs antibodies.
Two Types of CD4bs Antibody Recognition
To define the structural modes of antibody recognition, we pro-
duced antigen-binding fragments (Fab) and crystallized these in
complex with extended core versions of the HIV-1 gp120 enve-
lope glycoprotein (Kwon et al., 2012). In addition to the four newly
identified antibodies, we determined structures for antibodies
from three donors with broadly neutralizing antibodies that had
not been characterized structurally: the VH3-30-derived anti-
body HJ16 from donor 242315 (Corti et al., 2010; North et al.,
2011) as well as the VH1-46-derived antibodies 1B2530 from
donor RU1 and 8ANC131 and 8ANC134 fromdonor RU8 (Scheid
et al., 2011). These eight new structures (Figure 1 and Table S2)
from seven distinct B cell lineages nearly double the number
of lineages with structurally defined CD4bs antibody-gp120
complex structures (Table S3).
Structures of HIV-1 gp120 with antibodies from VH1-2 germ-
line (VRC18 and VRC27) or from VH1-46 germline (1B2530,
8ANC131, and 8ANC134) revealed antibody interfaces domi-
nated by the heavy-chain second complementarity determining
region (CDRH2) (Figure 2A). This ‘‘type,’’ or mode, of recognition
for both VH1-2- and VH1-46-derived antibodies was very similar,
although the binding angles of VH1-46-derived antibodies
relative to that of CD4 for 8ANC131 and 8ANC134 were on theCell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc. 1281
Figure 1. Crystal Structures of Eight CD4bs Antibodies in Complex with HIV-1 gp120 Show Similar Heavy- and Light-Chain Orientations
Complex structures are shown from a common alignment with gp120 (gray surface representation), with the light chains shown in blue and the heavy chains
shown in red, green, and brown for CDR H3-dominated recognizers, VH1-2-derived heavy chains, and VH1-46-derived heavy chains, respectively. See also
Figure S1 and Tables S1 and S2.outskirts of the strict confines of the VH1-2-derived antibodies
(Figure 2B). By contrast, structures of antibodies from germlines
other than VH1-2 or VH1-46 (VRC13, VRC16, andHJ16) revealed
antibody interfaces dominated by CDR H3, which in each case
contributed 75% of the heavy-chain interface (Figure 2A
and Table S4). Overall, structural analysis revealed broadly
neutralizing CD4bs antibodies to fall into two distinct types—
CDR H3-dominated or VH-gene-restricted—and also provided
characteristic features for each type of antibody recognition
(Table S3).
Conserved Geometry of CD4bs Recognition
Despite type-specific features, gp120-binding orientations of the
eight newly defined antibodies were similar to each other and to
previously determined structures from eight donors (Georgiev
et al., 2013; Liao et al., 2013; Wu et al., 2011; Zhou et al.,
2010, 2013) (Figure 2C). For the 15 unique broadly neutralizing
CD4bs lineages, the heavy chain comprised themajor interactive
component (77% ± 10% of the interface). For all 15, the light
chain was oriented toward the viral membrane (Figures 2D and
S2). Antibodies targeting the CD4bs were constrained geometri-
cally both in latitudinal accessibility, which defines freedom be-
tween viral and host cell membranes, and in longitudinal acces-
sibility, which defines freedom within the plane of the membrane
(relative to the viral spike, the latitudinal axis is perpendicular to
the trimer axis, and the longitudinal axis is parallel to this axis).
While the VH-gene-restricted antibodies clustered with similar
latitudinal angles, the four antibodies of the CDR H3-dominated
type each showed latitudes, which were similar to that of CD4
(Figure 2C, left and upper-right panels). The constraint in longi-
tude was also pronounced (Figure 2C, middle and lower-right
panels), with most longitudes within 20. Overall, the restriction
in binding orientation appeared to be substantially greater than
observed with antibodies against model antigens such as hen-1282 Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc.egg white lysozyme (Braden et al., 1994; Desmyter et al., 1996;
Padlan et al., 1989) or against other supersites of HIV-1 vulnera-
bility, such as the membrane-proximal external region on gp41,
where antibodies 2F5, 4E10, and 10E8 have divergent binding
orientations (Cardoso et al., 2005; Huang et al., 2012; Ofek
et al., 2004), or the glycan-V3 supersite on gp120, where longitu-
dinal approach angles ranged from 15 to 95 degrees among
four representative antibodies (PGT122, PGT128, PGT135, and
2G12) (Calarese et al., 2003; Julien et al., 2013; Kong et al.,
2013; Pejchal et al., 2011) (Figure S3).
To gain an overall understanding of the relationship between
breadth of neutralization and binding orientation, we compared
the orientation of CD4bs antibodies relative to the most effective
CD4bs antibodies thus far developed, modified somatic variants
of the VRC01 lineage such as antibody 45-46m2 or antibody
VRC07-523 (Diskin et al., 2013; Diskin et al., 2011; Rudicell
et al., 2014) (PDB: 4JKP and 4OLW). For this analysis, we added
three CDR H3-dominated recognizers—b12, b13, and F105—to
the current panel of 16 antibodies (Chen et al., 2009; Zhou et al.,
2007). Strong correlation between antibody orientation and
neutralization breadth was observed (p < 0.0001, R2 = 0.64),
with the VH1-2-derived antibodies that were the most similar in
angular orientation to antibodies 45-46m2 and VRC07-523 also
showing the highest breadth, and these were followed by VH1-
46 antibodies and CDR H3-dominated recognizers (Figure 3,
top). Separate correlations of CDR H3-dominated and VH-
gene-restricted CD4bs relative to the most effective antibody
of each type also showed strong correlation (Figure 3, middle
and bottom panels). Altogether, effective CD4bs antibodies
shared highly similar orientations, both in terms of overall
antibody angle of approach and in terms of heavy-light chain
orientation relative to the spike (Figures 2 and 3). However,
the two different types of antibodies—CDR H3-dominated
and VH-gene-restricted—correlated better with breadth when
Figure 2. Broadly Neutralizing CD4bs Antibodies Fall into Two Types: CDR H3-Dominated and VH-Gene-Restricted
(A) Percent of surface area buried in the gp120 interface for each CDR of heavy chain (left) and light chain (right).
(B) Orientation of heavy-chain component of CD4bs antibody on gp120 relative to CD4. Structures determined here are shown as solid squares. Notably, newly
determined structures—8ANC131, VRC13, VRC16, and HJ16—have orientations that differ from the previously published VRC01-class and CH103 antibodies.
(C) Angles of approach for CD4bs antibodies on the trimer spike in its pre-fusion near-native conformation. (Left) The HIV-1 Env trimer is shown as a gray surface
withN-linked glycans in teal stick representation. The CD4-binding site on the outer domain of gp120 is represented as a yellow surface; the binding orientation of
CD4 (domains 1 and 2) is shownwith a yellow line; the binding orientations of CD4bs antibodies are shownwith a red line for CDRH3-dominated, green for VH1-2-
gene-restricted, and brown for VH1-46-gene-restricted. (Right) Histogram of explicit angles of approach are provided in the trimer coordinate system shown at
left in which a latitudinal angle of 0 coincides with the trimer 3-fold axis.
(D) Binding orientation for CDR H3-dominated and VH-gene-restricted CD4bs antibodies. The light chains of antibodies are colored in slate blue, and the heavy
chains are colored red for CDRH3-dominated antibodies, dark green for VH1-2-gene-restricted antibodies, and brown for VH1-46-restricted antibodies. See also
Figures S2 and S3, Table S3. and S4.
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Figure 3. Neutralization Breadth of CD4bs Antibodies Correlates
with Angular Difference from the Most Effective Antibodies
Correlation between antibody breadth and the angular difference of the heavy
chain relative to the most effective antibodies. (Top) All CD4bs antibodies
relative to the most effective antibody, VRC07-523. (Middle) CDR H3-domi-
nated antibodies relative to the most effective CDR H3-dominated antibody,
VRC13; (bottom) VH-gene-restricted antibodies relative to the most effective
VH-gene-restricted antibody, VRC07-523. For clarity, antibodies are only
labeled in the middle and lower panels. To determine a common reference
frame for calculations of angular difference, antibody-gp120 structures were
first aligned to a common reference frame based on core gp120; to determine
angular difference relative to the most effective antibody, a second super-
position was performed to align each antibody to the most effective antibody
referent; rotation angles determined from this second superposition are
shown.treated as separate groups, with CD4bs antibodies clustering
around two optimal structural modes of recognition, which
were embodied by the most effective antibodies of each type
(Figures 2 and 3).
B Cell Ontogenies
In addition to type, which reflects structural mode of recognition,
CD4bs antibodies can be delineated by class, which further
categorizes antibodies by their B cell ontogeny (Kwong and1284 Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc.Mascola, 2012; West et al., 2014). B cell ontogeny accounts
for genetic similarities in developmental pathways and also
includes maturation processes such as affinity for antigens that
initiate B cell maturation and degree of affinity maturation
required for neutralization breadth. Thus, a single type of recog-
nitionmay be achieved by different B cell ontogenies, resulting in
different classes of antibodies (Table S3). To define the class of
each of the CD4bs antibodies, we studied their ontogenies.
The ontogenies of VH1-2-derived CD4bs antibodies have
been defined previously. As a group, they are unified by (1)
very weak to undetectable binding to gp120 of germline
V-gene revertants of heavy and light chain in which the CDR
H3 or L3 are mature (gHgL) (Jardine et al., 2013; Klein et al.,
2013; McGuire et al., 2013; Mouquet et al., 2010; Scheid et al.,
2011; Zhou et al., 2010), (2) similarities in heavy-chain evolution
(Wu et al., 2011), and (3) a specific light-chain sequence signa-
ture (West et al., 2012; Zhou et al., 2013). These characteristics
define the VRC01 class of neutralizing antibodies, named for
the first member of this class, VRC01 (Wu et al., 2010) fromdonor
45 (Wu et al., 2015). Among the new antibodies described here,
VRC18 and VRC27 are members of the VRC01 class.
When we analyzed the binding of gHgL revertants of the VH1-
46-derived antibodies, 8ANC131 and 1B2530, to a panel of full-
length gp120s, no detectable binding was observed, (Figure 4A),
similar to the behavior observed for VH1-2-derived VRC01 class
members (Scheid et al., 2011; Zhou et al., 2010). Cross-donor
phylogenetic analysis (Wu et al., 2011) indicated that the
VH1-46 derived antibodies from donors RU1 and RU8 evolved
with sufficient similarity to allow the identification of 8ANC131
sequences with 1B2530 sequence similarity and vice versa (Fig-
ure 4B and Table S5). We did not observe a specific heavy- or
light-chain signature. Moreover, whenwe analyzed immunogens
capable of binding the gHgL of VH1-2-derived antibodies
(McGuire et al., 2013), we found that the mature forms of anti-
bodies 1B2530 and 8ANC131 bound well to these immunogens,
but the gHgL of VH1-46-derived antibodies were unable to bind
(Figure S4). Thus, while the VH1-46-derived antibodies were
similar to those from the VRC01 class, the preponderance of
ontological features indicated VH1-46-derived antibodies to
form a separate class, whichwe named the 8ANC131 class, after
the most effective member of this class (Scheid et al., 2011).
For the CDR H3-dominated antibodies, only the ontogeny of
the CH103 antibody has been analyzed in detail previously
(Liao et al., 2013). None of the four CDR H3-dominated anti-
bodies analyzed here utilized the same origin genes (VH, D, JH,
VL/K, and JL/K) except CH103 and VRC13, which shared the
same Jl gene; however, because the light-chain J region did
not contribute substantially to recognition with either CH103 or
VRC13, the Jl usage was likely not critical to the ontogeny of
these antibodies. We tested the recognition of gHgL versions
of the four CDR H3-dominated antibodies: the gHgL of VRC13
and VRC16 showed weak and moderate binding to several
gp120s, while gHgL of CH103 and HJ16 showed no detectable
binding (Figure 4A). In terms of heavy-chain evolution, donor
samples for B cell sequencing were available from donors
44 and C38, the sources of antibodies VRC13 and VRC16,
respectively. Cross-donor analysis with heavy-chain sequences
showed no similarities in evolution between VRC13 and VRC16
Figure 4. Characteristics of B Cell Ontogenies for Effective CD4bs Antibodies
(A) Affinities for germline reverted (gHgL) and mature antibodies to six diverse gp120s. Clade of each isolate is shown in parentheses after the strain name.
(B) Similarities in heavy-chain maturation. Numbers in the table correspond to the number of heavy-chain sequences retrieved from heavy-chain transcripts
determined by NGS of B cells from each donor; retrieval was accomplished by cross-donor phylogenetic analysis with the template antibody from the first
column. Gray highlighted areas correspond to matching lineages and classes. The table diagonal represents matching antibodies and donors; when antibodies
are found off the diagonal, this indicates similarity in heavy-chain maturation.
(C) Class characteristics of effective CD4bs antibodies.
See also Figure S4 and Table S5.or between these antibodies and any of the sequences from
VH-gene-restricted donors (Figure 4B). Finally, we could not
identify any sequence signatures in the paratopes of the CDR
H3-dominated antibodies. In light of these data on gene origin,
gHgL recognition, heavy-chain evolution, and sequence signa-
ture, we conclude that antibodies CH103, HJ16, VRC13, andVRC16 each have different B cell ontogenies and therefore
represent separate antibody classes (Figure 4C and Table S3).
Epitope Characteristics of CD4bs Antibodies
To define the HIV-1-Env surface recognized by highly effective
antibodies from 14 donors, we analyzed their epitopes.Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc. 1285
Figure 5. The CD4 Supersite
(A) Antibodies from 14 donors define an immunological supersite of HIV-vulnerability. A composite of how the breadth-coded epitope surfaces shown in B are
mapped to the gp120 surface. The yellow outline defines the outer-domain contact of the CD4 receptor.
(B) Epitopes of CD4bs antibodies colored by breadth.
(C) Dendrogram constructed from similarities in neutralization fingerprint based on serologic analysis with a 178-virus panel; insert shows the HIV-1 viral spike,
with membrane at top, with major epitopes labeled; epitope colors correspond to antibody colors in the dendrogram.
(D) Potency of CD4-binding site antibodies mapped to the supersite. The worm representation of HIV-1 gp120 is colored by averaged antibody potency, with
thickness representing average buried binding surface area of corresponding residues; notably, in addition to the outer domain contact on gp120 for CD4,
neighboring regions in the inner domain and on strands b20/21 contribute to the supersite.
See also Figure S5.Recognized surfaces overlapped considerably, although sub-
stantial variation was observed with antibodies encoding CDR
H3-dominated recognition. For example, HJ16 recognized an
epitope that extended toward the viral membrane and shared
<50% overlap in recognized Env surface with VRC13. For the
VH-gene-restricted antibodies, epitope surfaces revealed a char-
acteristic discontinuity near the center of the epitope, a feature1286 Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc.shared with CD4 (Figures 5A and 5B). This discontinuity was
not observed for antibodieswithCDRH3-dominated recognition,
where the penetratingCDRH3 loops formed contiguous comple-
mentary molecular surfaces. To determine whether these differ-
ences in recognition could be detected functionally, we analyzed
the neutralization fingerprints (Georgiev et al., 2013) for all 16
CD4bs antibodies on a panel of 178 genetically diverse viruses
Figure 6. Paratopes of Effective CD4bs Antibodies Are Extremely Diverse
Recognition hot spots of CD4bs antibodies and CD4 are shown with antibodies labeled by class (top line) and representative member (bottom line).
(A) Recognition of the Phe43 cavity on gp120. Antibody or CD4 are shown in ribbon representation, with the side chain closest to the Phe43 cavity shown in stick
representation; gp120 is shown as a gray surface.
(B) Recognition of Asp368 on gp120. Coloring is the same as in A, but gp120 is shown in ribbon representation, with the Asp368 side chain in stick representation.
See also Figure S6 and Table S6.(Figure 5C). While the neutralization profile of CD4bs antibodies
segregated from antibodies targeting other Env sites, within the
CD4bs cluster, the most divergent were the VH1-46-derived
and CDR H3-dominated antibodies, with 1B2530 and HJ16 fall-
ing outside of the main CD4bs cluster. The remaining members
of the CD4bs classes were interleaved. To provide a per resi-
due understanding of the CD4 supersite, we combined recog-
nized epitope with neutralization potency to construct a resi-
due-level picture of the CD4 supersite (Figures 5D and S5).
Overall, despite differences in structural mode of recognition
and class, all of the CD4bs antibodies displayed general simi-
larities in terms of recognized epitope and profile of viruses
neutralized.
Paratope Characteristics of CD4bs Antibodies
To understand how these antibodies recognize the CD4 super-
site, we analyzed their paratopes. First, we structurally aligned
gp120 components from co-crystal structures and analyzed
known hot spots of CD4 interaction (Ryu et al., 1990; Wang
et al., 1990) (Figure 6) (for clarity, from this point forward, resi-
dues are displayed with a subscript defining the molecule).
Within domain 1 of CD4, Phe43CD4 makes contacts with the
‘‘Phe43 cavity’’ on gp120 and forms hydrophobic interactions
with Glu370gp120, Ile371gp120, and Trp427gp120 and backbone
contacts with residues 425gp120 and 473gp120 (Figure 6A and
Table S6). Interestingly, a similar hydrophobic interaction was
observed in some of the VH1-2-derived VRC01-class anti-
bodies, including Trp54VRC-PG20, Phe5412A21, and Phe54VRC27.
Despite this interaction being highly favorable (Diskin et al.,
2011; Rudicell et al., 2014), it was not preserved in other mem-
bers of the VRC01 class. For example, with VRC01, residue
54VRC01 is a glycine, and no hydrophobic residue substitutesfor this interaction (Figure 6A). For the VH1-46-derived anti-
bodies, no similar residue is found in 8ANC131, but for anti-
body 1B2530, Arg541B2530 engages the gp120 Phe43 cavity
in a manner similar to VH1-2 antibody VRC23. Meanwhile,
with the CDR H3-dominated antibodies, in VRC16, the phenyl
ring of Tyr100EVRC16 is oriented almost identically to that of
Phe43CD4, whereas in CH103, HJ16, and VRC13, no similar in-
teractions are observed; indeed, HJ16 does not even interact
with the Phe43 cavity (Figure S6). Thus, the specific chemical
interactions at the Phe43 cavity of gp120 appeared to be highly
variable.
In terms of the other highly favorable interaction within
domain 1 of CD4, Arg59CD4 forms electrostatic interactions
with Asp368gp120 (Figure 6B). With all of the VH-gene-restricted
type antibodies, both from VH1-2 and VH1-46 origins,
Arg71heavy chainmakes similar interactions.Notably, thecombina-
tion of a CDR H2-dominated interface along with use of
Arg71heavy chain may explain the restricted VH gene usage of this
antibody type. Many common VH genes encode Arg71heavy chain,
but this residue is often buried between CDR H2 and CDR H1
(North et al., 2011). VH1-2 and VH1-46 seem to possess CDR
H2 sequence features (such as Pro52A
heavy chain
) that lead to a
CDR H2 conformation that is compatible with gp120 binding
and that exposes Arg71heavy chain (see ‘‘Germline Gene Usage
of the VHGene-Restricted Antibodies’’ in Supplemental Informa-
tion). In the CDR H3-dominated antibodies, both CH103 and
VRC13 use Arg residues (Arg97CH103 and Arg96VRC13) to mimic
the interactionsofArg59CD4, but antibodyHJ16hasnoequivalent
interactions, and antibody VRC16 uses a His side chain to
approximate this interaction (Figure 6B). Thus, the specific chem-
ical interactions with Asp368gp120 appeared to bemostly, though
not entirely, conserved.Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc. 1287
Figure 7. Chemistry of CD4 Supersite Recognition by Effective Neutralizing Antibodies
(A) Chemistry of recognition surface for each of the CD4bs antibody classes and CD4. Each recognition surface is colored by atom types and presented from a
common reference frame, shown as the black outline of the CD4 contact surface on the gp120 outer domain. Antibody 8ANC131 is shown for the 8ANC131 class;
VRC01 is shown for the VRC01 class. Upper-left insets show representative members of each antibody class bound to the CD4 supersite on the HIV-1 Env trimer
(gray surface, with N-linked glycans shown in teal stick representation).
(B) Intra-class comparison of paratope atom type (top row, colored as in key for A) and somatic hypermutation (bottom row, with colors defined in key for B).
See also Figure S7 and Table S7.To provide an overall understanding of the recognition surface,
we analyzed paratope chemistry utilized in recognizing the CD4
supersite (Figure 7 and Table S7). We observed substantial inter-
class differences, with CDRH3-dominated antibodies displaying
especially varied binding surfaces and interactive chemistry. We
also examined intra-class differences between different donors
with antibodies derived from common VH genes (Figure 7B).
Among members of the VRC01 class (Figure 7B, left), paratope
chemistry and atom type (Petrey and Honig, 2000) were similar
despite the paratope being altered by substantial somatic hyper-
mutation. Notably, this hypermutation occurred in similar regions
of the paratope, likely reflecting similarities in ontogeny and in re-
quirements to achieve optimal recognition. Substantial diversity,
however, was observed among antibodies of the 8ANC131 class
from different donors (Figure 7B, right).
Thus, highly effective CD4bs antibodies, even those of the
same B cell ontogeny, can develop distinct paratope chemistry.1288 Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc.These differences in paratope chemistry indicate that the im-
mune system can find diverse solutions to the recognition of
the same target epitope.
DISCUSSION
While antibodies of the human immune system can recognize
epitopes in diverse ways, repeated observations in 14 donors
of similar geometries of recognition and similar B cell ontogenies
suggest the repertoire for broad neutralization to be relatively
limited. One potential explanation for this limitation is that
HIV-1 Env is so well protected from antibody recognition that
the humoral immune system can develop effective recogni-
tion—even against the more prevalently recognized supersites
of Env vulnerability—through only a few pathways.
It may be important to identify critical factors that constrain the
development of effective recognition, and one way to do this is
to analyze the recognition of multiple antibodies that target the
same supersite at the population level. Elements of diversity be-
tween these antibodies would indicate factors that allow the im-
mune system to develop multiple solutions; elements of similar-
ity would indicate dominant constraining factors. In the case of
the CD4 supersite, we observed the overall geometry of antibody
recognition to be highly similar (Figure 7A); this suggested a
dominant constraining factor for the elicitation of CD4bs anti-
bodies to be paratope accessibility at the recessed CD4 super-
site on functional viral spikes (Lyumkis et al., 2013; Pancera et al.,
2014).
The 14 donors analyzed here define our current understanding
of the human antibody repertoire that can effectively recognize
the CD4 supersite on HIV-1. While surrounded by glycan, the
surface that binds CD4 is itself free of glycan (Kwong et al.,
1998); indeed, it is the only epitope cluster on the HIV-1-Env
spike that is both glycan free and not membrane proximal (Pan-
cera et al., 2014). The VH-gene-restricted classes that success-
fully target this site each appear in multiple donors and share
evolutionary similarities, suggesting developmental pathways
accessible to the general population. By contrast, the CDR
H3-dominated classes each appear in a single donor and
show no detectable evolutionary similarity or sequence signa-
ture, suggesting origins that are stochastic and therefore not
shared between different individuals. Because the germline-re-
verted (gHgL) versions of the VH-gene-restricted and CDR H3-
dominated antibodies showed different binding behaviors to
gp120, we assessed their B cell activation properties to provide
insight into early development. Calcium flux experiments indi-
cated that B cell triggering could occur with gHgL versions of
VRC13, but not VRC01 (Figure S4), demonstrating differences
in ontogeny whereby germline versions of some CDR H3-domi-
nated antibodies could trigger B cell activation more efficiently
than germline-reverted versions of antibodies from VH-gene-
restricted classes. This was supported by the binding of the
germline-reverted version of the CDR H3-dominated VRC13
and VRC16 (Figure 4A), by the autologous-virus specific binding
of the unmutated common ancestor of the CDR H3-dominated
CH103 (Liao et al., 2013), and by the lack of binding for germ-
line-reverted versions of VH-gene-restricted antibodies (Figures
4 and S4) (Jardine et al., 2013; McGuire et al., 2013; Zhou et al.,
2010). Finally, the inability of germline-reverted VH1-46 anti-
bodies to bind immunogens, which had been developed to
recognize germline-reverted VH1-2 antibodies, indicated that
different classes of VH-gene-restricted antibodies may require
different immunogens. Together, the results suggest that
distinct immunogens may be required to stimulate the develop-
ment of the different types and classes of broadly neutralizing
antibodies that recognize the CD4 supersite.
Overall, the CD4bs antibody analysis described here, the first
comprehensive analysis of antibody recognition for a supersite
of HIV-1 vulnerability, provides a framework linking structural
mode of antibody recognition (type) with B cell ontogeny (class)
and paratope chemistry in 14 donors (Table S3). Serum from
these donors displayed a range of potencies though with
breadths generally in the upper range (Figure S7). This popula-
tion-level analysis provides insight into constraining factors
(e.g., from similarities in elicited antibodies) as well as the easeby which the immune system can replicate a particular lineage
pathway (e.g., from similarities in ontogeny). The results indicate
that the repertoire for effective recognition of the CD4 supersite
consists of antibodies with diverse paratopes that cluster around
two solutions: one achieved by VH-gene-restricted ontogenies
and the other achieved by CDR H3-dominated ontogenies. The
VH-gene-restricted solution, embodied by antibodies 45-46m2
and VRC07-523 (Diskin et al., 2013; Rudicell et al., 2014), uses
the CDR H2 region to mimic the C00 recognition of CD4 (Kwong
et al., 1998) though with a different latitudinal orientation to
accommodate the light chain (Zhou et al., 2010). The CDR H3-
dominated solution, embodied by antibody VRC13 isolated
here, uses the CDR H3 region to recognize the CD4 supersite,
with the same latitudinal angle as CD4. It will be interesting to
see whether additional broadly neutralizing CD4bs antibodies
will continue to cluster around these two solutions and whether
other highly effective solutions to the problem of antibody recog-
nition of the CD4 supersite can be found.
EXPERIMENTAL PROCEDURES
Human Specimens
Donors 44, C38, and Z258 participated in NIAID protocols (Doria-Rose et al.,
2009) at the National Institutes of Health, Bethesda, MD, USA. HIV infection
was documented by HIV-1/2 immunoassay. The donors were chronically in-
fected and had not initiated antiretroviral treatment at the time of sample
collection. All human samples were collected with informed consent under
clinical protocols approved by the appropriate institutional review board (IRB).
Isolation and Expression of Antibody 44-VRC13.01, C38-VRC16.01,
C38-VRC18.02, and Z258-VRC27.01
Antigen-specific memory B cells from donors 44, C38, and Z258 were isolated
with Avi-tagged RSC3 and DRSC3 and were single-cell sorted on a FACS Aria
II as described previously (Wu et al., 2010; Supplemental Experimental
Procedures)
Production and Purification of HIV-1 Env Protein and Antibodies
HIV-1 gp120 proteins were produced in GNTI/ cells and were purified as
described previously (Zhou et al., 2010). Human antibodies were expressed
in HEK293F cells and were purified by protein A affinity chromatography.
Antigen-binding fragments (Fab) of antibodies were prepared by overnight
Lys-C digestion at 37C with a IgG:Lys-C ratio of 4,000:1 (w/w) and sequential
purification over protein A and size exclusion columns.
Neutralization Assays
Single round of replication Env-pseudoviruses were prepared, titered, and
used to infect TZM-bl target cells as described previously (Montefiori, 2009)
(Supplemental Experimental Procedures and Table S1).
Formation of Protein Complexes, Crystallization, and Data
Collection
Antibody-gp120 complexes were formed by mixing deglycosylated HIV-1
gp120 with antibody Fab in a 1:1.2 molar ratio. The complexes were purified
by size exclusion chromatography. Fractions with antibody-gp120 complexes
were concentrated to 10 mg/ml for crystallization experiments. Crystalliza-
tion conditions for all gp120-Fab complexes were obtained robotically and
were manually optimized in hanging drops (Supplemental Experimental
Procedures).
Structure Determination and Refinement
Structures were solved by molecular replacement with Phaser (McCoy et al.,
2007). Iterative model building and refinement procedures were carried out
using Coot (Emsley and Cowtan, 2004) and Phenix (Adams et al., 2010) (Sup-
plemental Experimental Procedures and Table S2).Cell 161, 1280–1292, June 4, 2015 ª2015 Elsevier Inc. 1289
Bioinformatics Analysis of Antibody Neutralization and 454
Sequencing Data
The neutralization fingerprints of antibodies were analyzed with procedures
described previously (Georgiev et al., 2013). High-throughput B cell
sequencing of donor samples, bioinformatics processing of sequencing
data, and cross-donor phylogenetic analysis of antibody sequences were car-
ried out with similar procedures as described (Wu et al., 2011; Zhu et al., 2012;
Supplemental Experimental Procedures and Table S5)
Structural Analysis
All antibody complexes were aligned over the outer domain of HIV-1 gp120 to
gain a common reference frame for further comparison of the modes of recog-
nition to the CD4-binding site. The BG505.664 SOSIP crystal structure (PDB
ID: 4TVP) was used to analyze antibody recognition on the HIV-1 viral spike
(Pancera et al., 2014; Supplemental Experimental Procedures).
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